Skip to main content
Erschienen in: Supportive Care in Cancer 1/2016

01.01.2016 | Original Article

Using a personalized measure (Patient Generated Index (PGI)) to identify what matters to people with cancer

verfasst von: Ala’ S. Aburub, B. Gagnon, A. M. Rodríguez, Nancy E. Mayo

Erschienen in: Supportive Care in Cancer | Ausgabe 1/2016

Einloggen, um Zugang zu erhalten

Abstract

Purposes

Patient Generated Index (PGI) is designed to both ask and document quality of life (QOL) concerns. Its validity with respect to standard QOL measures has not been fully established for advanced cancer when QOL concerns predominate. The specific objective of this study is to identify, for people with advanced cancer, similarities and differences in ratings of global QOL between personalized and standard measures.

Methods

A total of 192 patients completed five QOL measures at study entry: PGI, generic measures (SF-6D, EQ-5D), and cancer-specific measures of QOL (McGill Quality of Life Questionnaire and Edmonton Symptoms Assessment Scale). Comparisons among total scores were compared using Generalized Estimating Equations (GEE).

Results

Patients voiced 114 areas of QOL concerns by the PGI with the top three being fatigue, sleep, and pain (39.2, 22.6, and 21.6 %, respectively). PGI total QOL score was 25 to 30 percentage points lower than those documented by the other measures, particularly when QOL was poor. Correlations between PGI and other measures were low.

Conclusion

PGI allowed patients to express a wide range of QOL concerns, many that were not assessed by other QOL measures. If only one QOL measure is to be included, either in a clinical setting or for research, the PGI would satisfy many of the criteria for “best choice.” PGI could be considered a cancer-specific QOL measure.

Implications for cancer

This study provides evidence that the PGI would be a good measure for patients and clinicians to use together to identify areas of concern that require attention and monitor changing needs.
Literatur
3.
Zurück zum Zitat Hoffman B (2005) Cancer survivors at work: a generation of progress. CA Cancer J Clin 55:271–280PubMedCrossRef Hoffman B (2005) Cancer survivors at work: a generation of progress. CA Cancer J Clin 55:271–280PubMedCrossRef
4.
Zurück zum Zitat Lehmann JF et al (1978) Cancer rehabilitation: assessment of need, development, and evaluation of a model of care. Arch Phys Med Rehabil 59(9):410–419PubMed Lehmann JF et al (1978) Cancer rehabilitation: assessment of need, development, and evaluation of a model of care. Arch Phys Med Rehabil 59(9):410–419PubMed
5.
Zurück zum Zitat Ness KK et al (2006) Physical performance limitations and participation restrictions among cancer survivors: a population-based study. Ann Epidemiol 16(3):197–205PubMedCrossRef Ness KK et al (2006) Physical performance limitations and participation restrictions among cancer survivors: a population-based study. Ann Epidemiol 16(3):197–205PubMedCrossRef
6.
Zurück zum Zitat O’Boyle CA et al (1992) Individual quality of life in patients undergoing hip replacement. Lancet 339(8801):1088–1091PubMedCrossRef O’Boyle CA et al (1992) Individual quality of life in patients undergoing hip replacement. Lancet 339(8801):1088–1091PubMedCrossRef
7.
Zurück zum Zitat Ruta DA et al (1994) A new approach to the measurement of quality of life. The Patient-Generated Index. Med Care 32(11):1109–1126PubMedCrossRef Ruta DA et al (1994) A new approach to the measurement of quality of life. The Patient-Generated Index. Med Care 32(11):1109–1126PubMedCrossRef
8.
Zurück zum Zitat Broadhead JK, Robinson JW, Atkinson MJ (1998) A new quality-of-life measure for oncology: The SEIQoL. J Psychosoc Oncol 16(1):21–35CrossRef Broadhead JK, Robinson JW, Atkinson MJ (1998) A new quality-of-life measure for oncology: The SEIQoL. J Psychosoc Oncol 16(1):21–35CrossRef
9.
Zurück zum Zitat Tavernier SS et al (2011) Validity of the Patient Generated Index as a quality-of-life measure in radiation oncology. Oncol Nurs Forum 38(3):319–329PubMedCrossRef Tavernier SS et al (2011) Validity of the Patient Generated Index as a quality-of-life measure in radiation oncology. Oncol Nurs Forum 38(3):319–329PubMedCrossRef
10.
Zurück zum Zitat Tavernier SS, Totten AM, Beck SL (2011) Assessing content validity of the patient generated index using cognitive interviews. Qual Health Res 21(12):1729–1738PubMedCrossRef Tavernier SS, Totten AM, Beck SL (2011) Assessing content validity of the patient generated index using cognitive interviews. Qual Health Res 21(12):1729–1738PubMedCrossRef
11.
Zurück zum Zitat Frick E, Tyroller M, Panzer M (2007) Anxiety, depression and quality of life of cancer patients undergoing radiation therapy: a cross-sectional study in a community hospital outpatient centre. Eur J Cancer Care 16(2):130–136CrossRef Frick E, Tyroller M, Panzer M (2007) Anxiety, depression and quality of life of cancer patients undergoing radiation therapy: a cross-sectional study in a community hospital outpatient centre. Eur J Cancer Care 16(2):130–136CrossRef
12.
Zurück zum Zitat Montgomery C et al (2002) Individual quality of life in patients with leukaemia and lymphoma. Psychooncology 11(3):239–243PubMedCrossRef Montgomery C et al (2002) Individual quality of life in patients with leukaemia and lymphoma. Psychooncology 11(3):239–243PubMedCrossRef
13.
Zurück zum Zitat Waldron D et al (1999) Quality-of-life measurement in advanced cancer: assessing the individual. J Clin Oncol 17(11):3603–3611PubMed Waldron D et al (1999) Quality-of-life measurement in advanced cancer: assessing the individual. J Clin Oncol 17(11):3603–3611PubMed
14.
Zurück zum Zitat Rodriguez AM, Mayo NE, Gagnon B (2013) Independent contributors to overall quality of life in people with advanced cancer. Br J Cancer 108(9):1790–1800PubMedCrossRef Rodriguez AM, Mayo NE, Gagnon B (2013) Independent contributors to overall quality of life in people with advanced cancer. Br J Cancer 108(9):1790–1800PubMedCrossRef
15.
Zurück zum Zitat Cohen SR et al (1997) Validity of the McGill Quality of Life Questionnaire in the palliative care setting: a multi-centre Canadian study demonstrating the importance of the existential domain. Palliat Med 11(1):3–20PubMedCrossRef Cohen SR et al (1997) Validity of the McGill Quality of Life Questionnaire in the palliative care setting: a multi-centre Canadian study demonstrating the importance of the existential domain. Palliat Med 11(1):3–20PubMedCrossRef
16.
Zurück zum Zitat Osoba D, King M (2005) Meaningful differences. In: Fayers PM, Hays RD (eds) Assessing quality of life in clinical trials, 2 edn. Oxford University Press, New York, pp. 243–257 p. 5 A.D. 251 Osoba D, King M (2005) Meaningful differences. In: Fayers PM, Hays RD (eds) Assessing quality of life in clinical trials, 2 edn. Oxford University Press, New York, pp. 243–257 p. 5 A.D. 251
17.
Zurück zum Zitat Wilson IB, Cleary PD (1995) Linking clinical variables with health-related quality of life. A conceptual model of patient outcomes. JAMA 273(1):59–65PubMedCrossRef Wilson IB, Cleary PD (1995) Linking clinical variables with health-related quality of life. A conceptual model of patient outcomes. JAMA 273(1):59–65PubMedCrossRef
18.
Zurück zum Zitat Ruta DA, Garratt AM, Russell IT (1999) Patient centred assessment of quality of life for patients with four common conditions. Qual Health Care 8(1):22–29PubMedCentralPubMedCrossRef Ruta DA, Garratt AM, Russell IT (1999) Patient centred assessment of quality of life for patients with four common conditions. Qual Health Care 8(1):22–29PubMedCentralPubMedCrossRef
19.
Zurück zum Zitat Camilleri-Brennan J, Ruta DA, Steele RJ (2002) Patient generated index: new instrument for measuring quality of life in patients with rectal cancer. World J Surg 26(11):1354–1359PubMedCrossRef Camilleri-Brennan J, Ruta DA, Steele RJ (2002) Patient generated index: new instrument for measuring quality of life in patients with rectal cancer. World J Surg 26(11):1354–1359PubMedCrossRef
20.
Zurück zum Zitat Lewis S et al (2002) Quality of life issues identified by palliative care clients using two tools. Contemp Nurse 12(1):31–41PubMedCrossRef Lewis S et al (2002) Quality of life issues identified by palliative care clients using two tools. Contemp Nurse 12(1):31–41PubMedCrossRef
21.
Zurück zum Zitat Llewellyn CD, McGurk M, Weinman J (2006) Head and neck cancer: to what extent can psychological factors explain differences between health-related quality of life and individual quality of life? Br J Oral Maxillofac Surg 44(5):351–357PubMedCrossRef Llewellyn CD, McGurk M, Weinman J (2006) Head and neck cancer: to what extent can psychological factors explain differences between health-related quality of life and individual quality of life? Br J Oral Maxillofac Surg 44(5):351–357PubMedCrossRef
23.
Zurück zum Zitat EuroQOL Group (1990) EuroQol—a new facility for the measurement of health-related quality of life. Health Policy 16(3):199–208CrossRef EuroQOL Group (1990) EuroQol—a new facility for the measurement of health-related quality of life. Health Policy 16(3):199–208CrossRef
24.
Zurück zum Zitat Gudex C et al. (1996) Health state valuations from the general public using the visual analogue scale. Qual Life Res 5(6):521–531PubMedCrossRef Gudex C et al. (1996) Health state valuations from the general public using the visual analogue scale. Qual Life Res 5(6):521–531PubMedCrossRef
25.
26.
Zurück zum Zitat Bansback N et al (2012) Canadian valuation of EQ-5D health states: preliminary value set and considerations for future valuation studies. PLoS One 7(2):e31115PubMedCentralPubMedCrossRef Bansback N et al (2012) Canadian valuation of EQ-5D health states: preliminary value set and considerations for future valuation studies. PLoS One 7(2):e31115PubMedCentralPubMedCrossRef
27.
Zurück zum Zitat Oremus M et al (2014) Health utility scores in Alzheimer’s disease: differences based on calculation with American and Canadian preference weights. Value Health 17(1):77–83PubMedCrossRef Oremus M et al (2014) Health utility scores in Alzheimer’s disease: differences based on calculation with American and Canadian preference weights. Value Health 17(1):77–83PubMedCrossRef
28.
Zurück zum Zitat Shaw JW, Johnson JA, Coons SJ (2005) US valuation of the EQ-5D health states: development and testing of the D1 valuation model. Med Care 43(3):203–220PubMedCrossRef Shaw JW, Johnson JA, Coons SJ (2005) US valuation of the EQ-5D health states: development and testing of the D1 valuation model. Med Care 43(3):203–220PubMedCrossRef
29.
Zurück zum Zitat Lee JA et al (2014) Comparison of health-related quality of life between cancer survivors treated in designated cancer centers and the general public in Korea. Jpn J Clin Oncol 44(2):141–152PubMedCrossRef Lee JA et al (2014) Comparison of health-related quality of life between cancer survivors treated in designated cancer centers and the general public in Korea. Jpn J Clin Oncol 44(2):141–152PubMedCrossRef
30.
Zurück zum Zitat Shim EJ et al (2011) Comprehensive needs assessment tool in cancer (CNAT): the development and validation. Support Care Cancer 19(12):1957–1968PubMedCrossRef Shim EJ et al (2011) Comprehensive needs assessment tool in cancer (CNAT): the development and validation. Support Care Cancer 19(12):1957–1968PubMedCrossRef
31.
Zurück zum Zitat Glick HA et al (1998) Empirical criteria for the selection of quality-of-life instruments for the evaluation of peripheral blood progenitor cell transplantation. Int J Technol Assess Health Care 14(3):419–430PubMedCrossRef Glick HA et al (1998) Empirical criteria for the selection of quality-of-life instruments for the evaluation of peripheral blood progenitor cell transplantation. Int J Technol Assess Health Care 14(3):419–430PubMedCrossRef
32.
Zurück zum Zitat Pickard AS et al (2007) Health utilities using the EQ-5D in studies of cancer. PharmacoEconomics 25(5):365–384PubMedCrossRef Pickard AS et al (2007) Health utilities using the EQ-5D in studies of cancer. PharmacoEconomics 25(5):365–384PubMedCrossRef
33.
Zurück zum Zitat Brazier J, Roberts J, Deverill M (2002) The estimation of a preference-based measure of health from the SF-36. J Health Econ 21(2):271–292PubMedCrossRef Brazier J, Roberts J, Deverill M (2002) The estimation of a preference-based measure of health from the SF-36. J Health Econ 21(2):271–292PubMedCrossRef
34.
Zurück zum Zitat Hever, N.V., et al (2014) Health related quality of life in patients with bladder cancer: a cross-sectional survey and validation study of the Hungarian version of the bladder cancer index. Pathol Oncol Res Hever, N.V., et al (2014) Health related quality of life in patients with bladder cancer: a cross-sectional survey and validation study of the Hungarian version of the bladder cancer index. Pathol Oncol Res
35.
Zurück zum Zitat Gallop K et al (2015) A qualitative evaluation of the validity of published health utilities and generic health utility measures for capturing health-related quality of life (HRQL) impact of differentiated thyroid cancer (DTC) at different treatment phases. Qual Life Res 24(2):325–338PubMedCrossRef Gallop K et al (2015) A qualitative evaluation of the validity of published health utilities and generic health utility measures for capturing health-related quality of life (HRQL) impact of differentiated thyroid cancer (DTC) at different treatment phases. Qual Life Res 24(2):325–338PubMedCrossRef
36.
37.
Zurück zum Zitat Lee L et al (2013) Valuing postoperative recovery: validation of the SF-6D health-state utility. J Surg Res 184(1):108–114PubMedCrossRef Lee L et al (2013) Valuing postoperative recovery: validation of the SF-6D health-state utility. J Surg Res 184(1):108–114PubMedCrossRef
38.
Zurück zum Zitat Barton GR et al (2008) An assessment of the discriminative ability of the EQ-5D index, SF-6D, and EQ VAS, using sociodemographic factors and clinical conditions. Eur J Health Econ 9(3):237–249PubMedCrossRef Barton GR et al (2008) An assessment of the discriminative ability of the EQ-5D index, SF-6D, and EQ VAS, using sociodemographic factors and clinical conditions. Eur J Health Econ 9(3):237–249PubMedCrossRef
39.
Zurück zum Zitat Hornbrook MC et al (2011) Complications among colorectal cancer survivors: SF-6D preference-weighted quality of life scores. Med Care 49(3):321–326PubMedCentralPubMedCrossRef Hornbrook MC et al (2011) Complications among colorectal cancer survivors: SF-6D preference-weighted quality of life scores. Med Care 49(3):321–326PubMedCentralPubMedCrossRef
40.
Zurück zum Zitat Bruera E et al (1991) The Edmonton Symptom Assessment System (ESAS): a simple method for the assessment of palliative care patients. J Palliat Care 7(2):6–9PubMed Bruera E et al (1991) The Edmonton Symptom Assessment System (ESAS): a simple method for the assessment of palliative care patients. J Palliat Care 7(2):6–9PubMed
41.
Zurück zum Zitat Cohen SR et al (2001) Changes in quality of life following admission to palliative care units. Palliat Med 15(5):363–371PubMedCrossRef Cohen SR et al (2001) Changes in quality of life following admission to palliative care units. Palliat Med 15(5):363–371PubMedCrossRef
42.
Zurück zum Zitat Cohen SR, Mount BM (2000) Living with cancer: “good” days and “bad” days—what produces them? Can the McGill quality of life questionnaire distinguish between them? Cancer 89(8):1854–1865PubMedCrossRef Cohen SR, Mount BM (2000) Living with cancer: “good” days and “bad” days—what produces them? Can the McGill quality of life questionnaire distinguish between them? Cancer 89(8):1854–1865PubMedCrossRef
43.
Zurück zum Zitat Cohen SR et al (1995) The McGill Quality of Life Questionnaire: a measure of quality of life appropriate for people with advanced disease. A preliminary study of validity and acceptability. Palliat Med 9(3):207–219PubMedCrossRef Cohen SR et al (1995) The McGill Quality of Life Questionnaire: a measure of quality of life appropriate for people with advanced disease. A preliminary study of validity and acceptability. Palliat Med 9(3):207–219PubMedCrossRef
44.
Zurück zum Zitat Cohen SR et al (1996) Existential well-being is an important determinant of quality of life. Evidence from the McGill Quality of Life Questionnaire. Cancer 77(3):576–586PubMedCrossRef Cohen SR et al (1996) Existential well-being is an important determinant of quality of life. Evidence from the McGill Quality of Life Questionnaire. Cancer 77(3):576–586PubMedCrossRef
45.
Zurück zum Zitat Nekolaichuk CL et al (1999) Assessing the reliability of patient, nurse, and family caregiver symptom ratings in hospitalized advanced cancer patients. J Clin Oncol 17(11):3621–3630PubMed Nekolaichuk CL et al (1999) Assessing the reliability of patient, nurse, and family caregiver symptom ratings in hospitalized advanced cancer patients. J Clin Oncol 17(11):3621–3630PubMed
46.
Zurück zum Zitat Chang VT, Hwang SS, Feuerman M (2000) Validation of the Edmonton Symptom Assessment Scale. Cancer 88(9):2164–2171PubMedCrossRef Chang VT, Hwang SS, Feuerman M (2000) Validation of the Edmonton Symptom Assessment Scale. Cancer 88(9):2164–2171PubMedCrossRef
47.
Zurück zum Zitat Cohen SR et al (1996) Quality of life in HIV disease as measured by the McGill quality of life questionnaire. AIDS 10(12):1421–1427PubMedCrossRef Cohen SR et al (1996) Quality of life in HIV disease as measured by the McGill quality of life questionnaire. AIDS 10(12):1421–1427PubMedCrossRef
49.
Zurück zum Zitat Denlinger CS et al (2014) Survivorship: sleep disorders, version 1.2014. J Natl Compr Cancer Netw 12(5):630–642 Denlinger CS et al (2014) Survivorship: sleep disorders, version 1.2014. J Natl Compr Cancer Netw 12(5):630–642
50.
Zurück zum Zitat Dickerson SS et al (2014) Sleep-wake disturbances in cancer patients: narrative review of literature focusing on improving quality of life outcomes. Nat Sci Sleep 6:85–100PubMedCentralPubMedCrossRef Dickerson SS et al (2014) Sleep-wake disturbances in cancer patients: narrative review of literature focusing on improving quality of life outcomes. Nat Sci Sleep 6:85–100PubMedCentralPubMedCrossRef
51.
Zurück zum Zitat Moens K, Higginson IJ, Harding R (2014) Are there differences in the prevalence of palliative care-related problems in people living with advanced cancer and eight non-cancer conditions? A systematic review. J Pain Symptom Manag 48(4):660–677CrossRef Moens K, Higginson IJ, Harding R (2014) Are there differences in the prevalence of palliative care-related problems in people living with advanced cancer and eight non-cancer conditions? A systematic review. J Pain Symptom Manag 48(4):660–677CrossRef
52.
Zurück zum Zitat Olson K (2014) Sleep-related disturbances among adolescents with cancer: a systematic review. Sleep Med 15(5):496–501PubMedCrossRef Olson K (2014) Sleep-related disturbances among adolescents with cancer: a systematic review. Sleep Med 15(5):496–501PubMedCrossRef
53.
Zurück zum Zitat Otte JL et al (2015) Systematic review of sleep disorders in cancer patients: can the prevalence of sleep disorders be ascertained? Cancer Med 4(2):183–200PubMedCentralPubMedCrossRef Otte JL et al (2015) Systematic review of sleep disorders in cancer patients: can the prevalence of sleep disorders be ascertained? Cancer Med 4(2):183–200PubMedCentralPubMedCrossRef
54.
Zurück zum Zitat Aaronson NK et al (1993) The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst 85(5):365–376PubMedCrossRef Aaronson NK et al (1993) The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst 85(5):365–376PubMedCrossRef
55.
Zurück zum Zitat Letellier, M.E., D. Dawes, and N. Mayo (2014) Content verification of the EORTC QLQ-C30/EORTC QLQ-BR23 with the International Classification of Functioning, Disability and Health. Qual Life Res Letellier, M.E., D. Dawes, and N. Mayo (2014) Content verification of the EORTC QLQ-C30/EORTC QLQ-BR23 with the International Classification of Functioning, Disability and Health. Qual Life Res
56.
Zurück zum Zitat Cella DF et al (1993) The Functional Assessment of Cancer Therapy scale: development and validation of the general measure. J Clin Oncol 11(3):570–579PubMed Cella DF et al (1993) The Functional Assessment of Cancer Therapy scale: development and validation of the general measure. J Clin Oncol 11(3):570–579PubMed
57.
Zurück zum Zitat Dolan P (1999) Whose preferences count? Med Decis Mak 19(4):482–486CrossRef Dolan P (1999) Whose preferences count? Med Decis Mak 19(4):482–486CrossRef
58.
Zurück zum Zitat Kuspinar A, Mayo NE (2013) Do generic utility measures capture what is important to the quality of life of people with multiple sclerosis? Health Qual Life Outcomes 11:71PubMedCentralPubMedCrossRef Kuspinar A, Mayo NE (2013) Do generic utility measures capture what is important to the quality of life of people with multiple sclerosis? Health Qual Life Outcomes 11:71PubMedCentralPubMedCrossRef
59.
60.
Zurück zum Zitat Norman GR, Sloan JA, Wyrwich KW (2003) Interpretation of changes in health-related quality of life: the remarkable universality of half a standard deviation. Med Care 41(5):582–592PubMed Norman GR, Sloan JA, Wyrwich KW (2003) Interpretation of changes in health-related quality of life: the remarkable universality of half a standard deviation. Med Care 41(5):582–592PubMed
61.
Zurück zum Zitat McHorney CA, Tarlov AR (1995) Individual-patient monitoring in clinical practice: are available health status surveys adequate? Qual Life Res 4(4):293–307PubMedCrossRef McHorney CA, Tarlov AR (1995) Individual-patient monitoring in clinical practice: are available health status surveys adequate? Qual Life Res 4(4):293–307PubMedCrossRef
Metadaten
Titel
Using a personalized measure (Patient Generated Index (PGI)) to identify what matters to people with cancer
verfasst von
Ala’ S. Aburub
B. Gagnon
A. M. Rodríguez
Nancy E. Mayo
Publikationsdatum
01.01.2016
Verlag
Springer Berlin Heidelberg
Erschienen in
Supportive Care in Cancer / Ausgabe 1/2016
Print ISSN: 0941-4355
Elektronische ISSN: 1433-7339
DOI
https://doi.org/10.1007/s00520-015-2821-7

Weitere Artikel der Ausgabe 1/2016

Supportive Care in Cancer 1/2016 Zur Ausgabe

Adjuvante Immuntherapie verlängert Leben bei RCC

25.04.2024 Nierenkarzinom Nachrichten

Nun gibt es auch Resultate zum Gesamtüberleben: Eine adjuvante Pembrolizumab-Therapie konnte in einer Phase-3-Studie das Leben von Menschen mit Nierenzellkarzinom deutlich verlängern. Die Sterberate war im Vergleich zu Placebo um 38% geringer.

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

25.04.2024 NSCLC Nachrichten

Das Risiko für Rezidiv oder Tod von Patienten und Patientinnen mit reseziertem ALK-positivem NSCLC ist unter einer adjuvanten Therapie mit dem Tyrosinkinase-Inhibitor Alectinib signifikant geringer als unter platinbasierter Chemotherapie.

Bei Senioren mit Prostatakarzinom auf Anämie achten!

24.04.2024 DGIM 2024 Nachrichten

Patienten, die zur Behandlung ihres Prostatakarzinoms eine Androgendeprivationstherapie erhalten, entwickeln nicht selten eine Anämie. Wer ältere Patienten internistisch mitbetreut, sollte auf diese Nebenwirkung achten.

ICI-Therapie in der Schwangerschaft wird gut toleriert

Müssen sich Schwangere einer Krebstherapie unterziehen, rufen Immuncheckpointinhibitoren offenbar nicht mehr unerwünschte Wirkungen hervor als andere Mittel gegen Krebs.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.